Background
Cristina Adriana Popa
The Protein Pendulum in CKD: supplement or ...

This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.

The Protein Pendulum in CKD: supplement or restrict?
Background, summary
Brian Rifkin
Chimerism and Immune Tolerance: Can We Says ...

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?
Meta
joel topf
NephJC 2025 Fall Pledge Drive

Help keep NephJC a vital, original, and unbiased source of medical education.

NephJC 2025 Fall Pledge Drive
Background, summary
Brian Rifkin
PREVENT, Detect, Treat: What’s New in the 2025 ...

This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

PREVENT, Detect, Treat: What’s New in the 2025 Hypertension Toolkit
Background
swapnil hiremath
In ESRD is spironolactone an overACHIEVEr?

This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?

In ESRD is spironolactone an overACHIEVEr?

trial

,

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

,
Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

REGENCY: A B-Cell Super Destroyer in Lupus

REGENCY: A B-Cell Super Destroyer in Lupus

This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨

HDF vs HD: Need for CONVINCE-ing Evidence

HDF vs HD: Need for CONVINCE-ing Evidence

This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?